Tropical Travel Trouble 009 Humongous HIV Extravaganza
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog aka Tropical Travel Trouble 009 The diagnosis of HIV is no longer fatal and the term AIDS is becoming less frequent. In many countries, people with HIV are living longer than those with diabetes. This post will hopefully teach the basics of a complex disease and demystify some of the potential diseases you need to consider in those who are severely immunosuppressed. While trying to be comprehensive this post can not be exhaustive (as you can imagine any patient with ...
Source: Life in the Fast Lane - July 7, 2018 Category: Emergency Medicine Authors: Amanda McConnell Tags: Clinical Cases Tropical Medicine AIDS art cryptococcoma cryptococcus HIV HIV1 HIV2 PEP PrEP TB toxoplasma tuberculoma Source Type: blogs
I’m awaiting delivery of my next two weeks’ worth of medications with a major change in the blister packs. Gone will be Norvir, Prezista, Truvada and Nevirapine, all taken twice a day, and they’re being replaced with ONE pill, Genvoya, ONCE a day containing 4 new-to-me drugs in combination. What a relief, other pills continuing … Continue reading Pill relief (Source: My journey with AIDS)
Source: My journey with AIDS - December 13, 2017 Category: Infectious Diseases Authors: Kenn Tags: AIDS and HIV autobiography health-care medical update Source Type: blogs
A Year in Review: FDA 2015 New Drug Approvals
The approval of first-of-a-kind drugs rose last year to forty-one, resulting in the highest level of newly approved U.S. drugs in nineteen years. The total number of new drugs approved last year was even higher at sixty-nine. The rising figures reflect an industry-wide desire to research and develop drugs for rare and hard-to-treat diseases. The newly approved drugs serve to advance medical care and the health of patients suffering from many ailments, including various forms of cancer, heart failure, and cystic fibrosis. Additionally, more than 40% of the new therapies were approved for treatment of rare or "orphan&...
Source: Policy and Medicine - January 13, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week
January 29, 2015 Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for (Source: Nelson Vergel's HIV Blog)
Source: Nelson Vergel's HIV Blog - January 29, 2015 Category: Infectious Diseases Authors: Nelson Vergel Source Type: blogs
Janssen Engages HIV Community on Tumblr: Build It and They Will Come?
A few months ago, I engaged Peter Houston (@Flipping_Pages) in a discussion about whether or not pharma "should" do Tumblr, a social media site that allows users to post text, photos, quotes, links, music, and videos from browsers, phones, via email or wherever (see "Should Pharma Do Tumblr?"). Here's some comments from Houton regarding Tumblr's youthful user base, which I thought was inappropriate for pharma: Could Pharma Use Tumblr and Survive? In this 3-minute audio snippet, Peter Houston, founder of Flipping Pages Media Ltd, discusses the pros and cons of Tumblr and whether it is possibl...
Source: Pharma Marketing Blog - August 31, 2013 Category: Pharma Commentators Tags: Janssen Tumblr Johnson and Johnson social media HIV Source Type: blogs
Medicines Patent Pool Has Another Big Pharma Deal
For the past two years, the Medicines Patent Pool has largely met with indifference from the pharmaceutical industry. Only one drugmaker, Gilead Sciences, agreed to license any of its medicines to the non-profit initiative, which was created by UNITAID to streamline licensing so that generic versions of patented HIV meds could be offered at lower prices in poor countries. Now, though, after extensive lobbying and negotiations another drugmaker has signed on. ViiV Healthcare, which is a joint venture between GlaxoSmithKline (GSK) and Pfizer, has agreed to license abacavir, also known as Ziagen,for children. MPP and ViiV hav...
Source: Pharmalot - February 27, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized Abacavir AIDS Dolutegravir Gilead Sciences GlaxoSmithKline HIV Pfizer Unitaid Viiv Healthcare Ziagen Source Type: blogs
Three Rings in a Row
Here's a structure that caught me eye, in this paper from Georgia State and Purdue. That's a nice-looking group stuck on the side of their HIV protease inhibitor; I don't think I've ever seen three fused THF rings before, and if I have, it certainly wasn't in a drug candidate. From the X-ray structure, it seems to be making some beneficial interactions out in the P2 site. This is an analog these are analogs of darunavir, which has two THFs fused in similar fashion. That compound's behavior in vivo is well worked out - most of the metabolism is cleavage of the carbamate. Both with and without that, there's a bunch of scatt...
Source: In the Pipeline - January 24, 2013 Category: Chemists Tags: Infectious Diseases Source Type: blogs